The funding of biopharmaceutical research and development
The funding of biopharmaceutical research and development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. It addresses both private and public funding sources available in the US and internationally. The biop...
| Autor principal: | |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Cambridge :
Woodhead Publishing
2013.
|
| Edición: | 1st edition |
| Colección: | Woodhead Publishing series in biomedicine ;
no. 43. |
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009628725506719 |
Tabla de Contenidos:
- Cover; The funding of biopharmaceutical research and development; Copyright; Dedication; Contents; List of figures and tables; Glossary; Preface; About the author; 1. Introduction to the biopharmaceutical market; 1.1 Introduction; 1.2 Synopsis of the development of the biopharmaceutical market sector; 1.3 Global growth of research and biopharmaceuticals; 1.4 Biopharmaceutical and healthcare value chain; 1.5 Demand for biopharmaceuticals; 1.6 Approval process; 1.7 Generic medicines; 1.8 Pricing of drugs; 1.9 Summary; 1.10 References; 2. Synopsis of theories of the firm and valuation methods
- 2.1 Introduction2.2 The neoclassical perfect competition model; 2.3 Industrial organization economics; 2.4 Resource-based view of the firm; 2.5 Innovation and entrepreneurship; 2.6 Valuation; 2.7 Real options; 2.8 Final words on valuations; 2.9 Corporate control; 2.10 Summary; 2.11 References; 3. Innovation and the merging of the pharmaceutical and biotechnology industries; 3.1 Patents and patent protection; 3.2 Standards and S-curves; 3.3 Real options reasoning; 3.4 Proinnovation bias; 3.5 Summary; 3.6 References; 4. The funding of basic research and public-private partnerships
- 4.1 Introduction to research funding in the U.S.4.2 Research funding in the European Union; 4.3 Research funding in Asia; 4.4 Technology transfer; 4.5 Technology transfer offices; 4.6 Bioclusters; 4.7 Biocenters; 4.8 Spillovers and the diffusion of biopharmaceuticals; 4.9 Summary; 4.10 References; 5. Strategic alliances; 5.1 Introduction to strategic alliances; 5.2 Forms of strategic alliances; 5.3 Models of the management of multiple alliances; 5.4 Not all alliances are strategic; 5.5 Opportunism in strategic alliances; 5.6 Summary; 5.7 References; 6. Angel and venture capital
- 6.1 Introduction to angel investors and venture capital6.2 Venture capital staging; 6.3 Venture capital history; 6.4 Ownership structure; 6.5 Venture capital and the entrepreneur; 6.6 Venture capital around the world; 6.7 Summary; 6.8 References; 7. The initial public offering; 7.1 An introduction to the initial public offering; 7.2 A brief synopsis of the history of stock exchanges; 7.3 The IPO process in the United States; 7.4 IPOs around the U.S.; 7.5 Research and development expenditures and fi nancial condition; 7.6 IPO performance; 7.7 Venture capital involvement; 7.8 IPO as exit
- 7.9 IPO activity around the world7.10 Summary; 7.11 References; 8. Conclusion; 8.1 Reference; Index
